Incidence, Timing, and Long-Term Outcomes of COVID-19 Vaccine-Related Lymphadenopathy on Screening Mammography.

Leslie R Lamb¹, Sarah F Mercaldo², Andrew Carney², Alexander Leyva², Helen Anne D'Alessandro², Constance D Lehman³

¹Co-Director of Breast Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: lrlamb@mgh.harvard.edu.

²Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.

³Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Founder & Co-Director of Breast Imaging Research Center at Massachusetts General Hospital and Co-Founder of Clairity, Inc.

PubMed DOI

Abstract

OBJECTIVE: To determine the incidence, timing, and long-term outcomes of unilateral axillary lymphadenopathy ipsilateral to vaccine site (UIAL) on screening mammography after COVID-19 vaccination. METHODS: This retrospective, multisite study included consecutive patients undergoing screening mammography February 8, 2021, to January 31, 2022, with at least 1 year of follow-up. UIAL was typically c…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.